Advances in Clinical Pharmacology in Lung Cancer—2nd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 6
Special Issue Editor
2. School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
3. Lung Cancer Team, Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Interests: lung cancer; target therapy; immunotherapy; antiangiogenic agent; chemotherapy; NGS
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are excited to launch the second edition of this Special Issue on the topic of advances in clinical pharmacology in lung cancer (https://www.mdpi.com/journal/cancers/special_issues/2KVP0U08G8).
Lung cancer has always been the deadliest cancer worldwide, largely due to being difficult to detect, meaning that it is often only discovered in its advanced stages. Since the development of EGFR TKI-targeted therapy, precision medicine has been increasingly implemented in lung cancer. With the integration of next-generation sequencing (NGS) technologies, various driver genes have been validated through clinical trials and real-world data, showing significant improvements in patient response rates, disease progression-free periods, and even survival rates compared to traditional chemotherapy. Beyond targeted therapies, the combined use of anti-angiogenesis drugs and the development of immunotherapy have set milestones in lung cancer treatment. These advances apply not only to systemic treatments in stage four lung cancer but also to earlier-stage lung cancer, where patients can receive them as neoadjuvant or adjuvant therapy, offering hope regarding long-term survival. In this Special Issue, we will further explore and discuss the pharmacological aspects and applications of these drugs, with the aim of contributing to advancing the treatment of lung cancer.
Prof. Dr. Chih-Jen Yang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- target therapy
- immunotherapy
- antiangiogenic agent
- chemotherapy
- NGS
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
